Navigation Links
New drug successfully halts fibrosis in animal model of liver disease
Date:8/7/2012

A study published in the online journal Hepatology reports a potential new NADPH oxidase (NOX) inhibitor therapy for liver fibrosis, a scarring process associated with chronic liver disease that can lead to loss of liver function.

"While numerous studies have now demonstrated that advanced liver fibrosis in patients and in experimental rodent models is reversible, there is currently no effective therapy for patients," said principal investigator David A. Brenner, MD, vice chancellor for Health Sciences and dean of the School of Medicine at the University of California, San Diego. "This new study provides important validation of the role of NOX in liver fibrosis, and suggests that a NOX inhibitor could provide an effective treatment for this devastating disease."

Most chronic liver diseases are associated with progressive fibrosis, which is triggered by the loss of liver cells and the activation of inadequate wound healing pathways. In addition, oxidative stress which results from an inappropriate balance between the production and clearance of highly reactive molecules involved in cell signaling called reactive oxidative species (ROS) leads to aberrant tissue repair in the liver.

When the liver is injured for example, through hepatitis or alcohol abuse HSCs are activated to become myofibroblasts, cells which play a crucial role in wound healing and the body's response to inflammation by recruiting immune cells called macrophages to the injury site. This process, triggered by intracellular signalling pathways involving NOX, can result in an abundance of scarring and eventually result in the loss of organ function.

By inhibiting NOX, the researchers theorized that myofibroblast activation and macrophage recruitment could be interrupted, preventing further fibrosis and potentially allowing regression of established fibrosis.

They assessed the effectiveness of treatment with GKT137831 a NOX1/4 inhibitor developed by Genkyotex SA of Geneva, Switzerland in mouse models, and found that treatment with this NOX inhibitor suppressed ROS production, as well as NOX and fibrotic gene expression.

"These data highlight the excellent pharmacological properties of GKT137831 and the broad potential for its use in fibrotic diseases,'' said Patrick Page, chief development officer at Genkyotex and contributor to the study.

According to Brenner, the next steps include a clinical trial with this drug in patients with liver fibrosis.


'/>"/>

Contact: Debra Kain
ddkain@ucsd.edu
619-543-6163
University of California - San Diego
Source:Eurekalert

Related medicine news :

1. CNIO scientists successfully test the first gene therapy against aging-associated decline
2. Ben-Gurion U. researchers successfully test solar desalination system for arid land agriculture
3. Study evaluates use of inhaled saline for young children with cystic fibrosis
4. Feola, at University of Kentucky, receives NIH grant to study cystic fibrosis
5. GW researchers discover biomarker for advanced bile duct fibrosis and bile duct cancer
6. Researchers develop a new cell and animal model of inflammatory breast cancer
7. FDA Seeks to Limit Antibiotics in Animal Feed
8. Animals More Interesting to Kids Than Toys, Study Shows
9. Raucous Music May Tap Into Your Inner Animal
10. Recruiting for Good Launches Pet Philanthropy Program to Collaboratively Fundraise for Kitt Crusaders an Animal Rescue Organization
11. Woodbridge Animal Hospital Unleashes New Pet Care Website
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... ProVest Insurance Group, ... Dallas, Miami, and Raleigh regions, is organizing an extended charity drive to benefit ... deadly chromosome abnormality. , After struggling since birth with several health challenges, T.J. ...
(Date:10/13/2017)... ... , ... As health professionals work to improve their approach to healthcare, there ... more than filling out a survey; in many cases health professionals and patients are ... care and research on the importance of active engagement with patients and members of ...
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's (ABFM) ... and Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton ... until Dr. Puffer’s retirement at the end of 2018. Upon assuming the role of ...
(Date:10/13/2017)... ... , ... PurhealthRX , a leading Health and Nutrition Company, is announcing ... full spectrum CBD oil will revolutionize the rapidly growing CBD market by reducing the ... incorporated into liquid products, while reducing costs to end users. , The team of ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder ... of ElderCounsel, a national organization of elder law and special needs planning attorneys. “Membership ... rules. It also provides a forum to network with elder law attorneys nationwide,” said ...
Breaking Medicine News(10 mins):
(Date:10/11/2017)... , Oct. 11, 2017  Caris Life Sciences ... on fulfilling the promise of precision medicine, today announced ... joined Caris, Precision Oncology Alliance™ (POA) as its 17 ... centers, the St. Jude Crosson Cancer Institute will help ... the use of tumor profiling, making cancer treatment more ...
(Date:10/11/2017)... Oct. 11, 2017  Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: ... facility in Las Piedras, Puerto Rico ... blades. Following ... facility sustained minor structural damage, temporary loss of power ... have been completed, manufacturing operations have resumed, and the ...
(Date:10/10/2017)...   West Pharmaceutical Services, Inc. (NYSE: WST), ... administration, today shared the results of a study highlighting ... intradermal administration of polio vaccines. The study results were ... 2017 by Dr. Ondrej Mach , Clinical Trials ... (WHO), and recently published in the journal Vaccine. ...
Breaking Medicine Technology: